| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 |
| filingDate |
2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41a1d84e04e5e564290d3970af3311f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e6d59ef5ac058957329141272972b4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2372cf9a142576aa1e643025089aba4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f1601bed68a8fd09dc1998234416d4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5b83037a7ff4e76bff7975fbd0079db |
| publicationDate |
2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020060087-A1 |
| titleOfInvention |
Highly efficient anti-tfpi antibody composition |
| abstract |
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease. |
| priorityDate |
2018-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |